You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 4,873,316

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,873,316

Title:	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
Abstract:	This invention relates to the production of recombinant proteins in mammals\' milk. Particularly, this invention relates to an expression system comprising the mammal\'s casein promoter which when transgenically incorporated into a mammal permits the female species of that mammal to produce the desired recombinant protein in or along with its milk. This invention also relates to the transgenic mammal that produces the desired recombinant product in its milk.
Inventor(s):	Meade; Harry (Newton, MA), Lonberg; Nils (New York, NY)
Assignee:	Biogen, Inc. (Cambridge, MA)
Application Number:	07/065,994
Patent Claims:	1. A process for the production and secretion into mammal's milk of an exogenous recombinate protein comprising the steps of: a. producing milk in a transgenic mammal characterized by an expression system comprising a casein promoter operatively linked to an exogenous DNA sequence coding for the recombinant protein through a DNA sequence coding for a signal peptide effective in secreting and maturing the recombinant protein in mammary tissue; b. collecting the milk; and c. isolating the exogenous recombinant protein from the milk. 2. The process according to claim 1, wherein said expression system also includes a 3' untranslated region downstream of the DNA sequence coding for the recombinant protein. 3. The process according to claim 1, wherein said expression system also includes a 5' untranslated region between said promoter and the DNA sequence coding for the signal peptide.

Details for Patent 4,873,316

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Baxalta Us Inc.	BIOCLATE (ARMOUR), RECOMBINATE	antihemophilic factor (recombinant)	For Injection	103375	12/10/1992	⤷ Try a Trial	2040-01-28
Baxalta Us Inc.	BIOCLATE (ARMOUR), RECOMBINATE	antihemophilic factor (recombinant)	For Injection	103375	03/10/2010	⤷ Try a Trial	2040-01-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.